ADMA Biologics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 559.92, 667.01, 783.25, 908.74, 1006.49 ], "ebit_estimate": [ 244.56, 315.67, 395.72, 480.99, 557.9 ], "ebitda_estimate": [ 279.98, 346.99, 421.12, 505.45, 607.72 ], "net_income_estimate": [ 197.37, 252.61, 312.7, 384.33, 448.55 ], "per_share_eps_estimate": [ 0.82, 1.03, 1.29, 1.58, 1.84 ], "eps_nri_estimate": [ 0.82, 1.03, 1.29, 1.58, 1.84 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.6, 1.48, null, null, null ], "pretax_income_estimate": [ 253.21, 314.79, 403.79, 496.19, 578.62 ], "operating_cash_flow_per_share_estimate": [ 8, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 68.95, 68.7, 70.75, 72.25, 73 ], "operating_cash_flow_estimate": [ 1919.65, null, null, null, null ], "pettm_estimate": [ 11.06, 8.82, 7.06, 5.76, 4.95 ], "long_term_growth_rate_mean": 28.69, "long_term_revenue_growth_rate_mean": "15.73", "future_per_share_eps_estimate_growth": 28.69, "future_eps_nri_estimate_growth": 28.69, "future_revenue_estimate_growth": 15.73, "future_ebit_estimate_growth": 27.55, "future_ebitda_estimate_growth": 22.33, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 28.56, "future_pretax_income_estimate_growth": 29.66, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 6.46, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 132.34, 144.81, 161.58, 156.81, 164.66, 175.3, 190.94 ], "ebit_estimate": [ 61.51, 70.7, 82.3, 66.03, 73.12, 79.77, 93.62 ], "ebitda_estimate": [ 63.49, 72.73, 84.34, 68.31, 73.83, 79.22, 87.31 ], "net_income_estimate": [ 46.48, 53.85, 63.11, 50.45, 56.3, 61.86, 72.9 ], "per_share_eps_estimate": [ 0.18, 0.21, 0.25, 0.21, 0.23, 0.26, 0.3 ], "eps_nri_estimate": [ 0.18, 0.21, 0.25, 0.21, 0.23, 0.26, 0.3 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 55.79, 65.06, 76.56, 65.95, 73.62, 80.92, 95.39 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 67, 68.5, 69.85, 66, 68, 70, 71 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 10.71, 10.12, 9.63, 9.15, null, null, null ], "long_term_growth_rate_mean": 28.69, "long_term_revenue_growth_rate_mean": "15.73", "future_per_share_eps_estimate_growth": 28.69, "future_eps_nri_estimate_growth": 28.69, "future_revenue_estimate_growth": 15.73, "future_ebit_estimate_growth": 27.55, "future_ebitda_estimate_growth": 22.33, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 28.56, "future_pretax_income_estimate_growth": 29.66, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 6.46, "future_operating_cash_flow_per_share_estimate_growth": null }